- Home
- CRF vs SPRY Comparison
CRF vs SPRY Comparison
Compare CRF & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRF
- SPRY
- Stock Information
- Founded
- CRF 1973
- SPRY 2015
- Country
- CRF United States
- SPRY United States
- Employees
- CRF N/A
- SPRY 24
- Industry
- CRF Finance/Investors Services
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- CRF Finance
- SPRY Health Care
- Exchange
- CRF Nasdaq
- SPRY Nasdaq
- Market Cap
- CRF 926.5M
- SPRY 1.2B
- IPO Year
- CRF N/A
- SPRY N/A
- Fundamental
- Price
- CRF $7.54
- SPRY $11.95
- Analyst Decision
- CRF
- SPRY Strong Buy
- Analyst Count
- CRF 0
- SPRY 5
- Target Price
- CRF N/A
- SPRY $26.80
- AVG Volume (30 Days)
- CRF 1.5M
- SPRY 1.3M
- Earning Date
- CRF 01-01-0001
- SPRY 03-20-2025
- Dividend Yield
- CRF 17.55%
- SPRY N/A
- EPS Growth
- CRF N/A
- SPRY N/A
- EPS
- CRF 1.40
- SPRY N/A
- Revenue
- CRF $11,461,786.00
- SPRY $2,568,000.00
- Revenue This Year
- CRF N/A
- SPRY $61,233.33
- Revenue Next Year
- CRF N/A
- SPRY $585.54
- P/E Ratio
- CRF $5.50
- SPRY N/A
- Revenue Growth
- CRF 6.53
- SPRY 8460.00
- 52 Week Low
- CRF $6.52
- SPRY $7.55
- 52 Week High
- CRF $9.75
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- CRF 31.71
- SPRY 55.76
- Support Level
- CRF $7.50
- SPRY $10.00
- Resistance Level
- CRF $7.75
- SPRY $11.55
- Average True Range (ATR)
- CRF 0.27
- SPRY 0.69
- MACD
- CRF -0.02
- SPRY 0.21
- Stochastic Oscillator
- CRF 10.84
- SPRY 78.00
About CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.